Key results of the AUGMENT study for patients with follicular lymphoma15
| Treatment arm . | Number of patients* . | ORR . | CRR . | PFS, median (mo) . | DOR, median (mo) . | 2-y OS . |
|---|---|---|---|---|---|---|
| Rituximab single agent | 148 | 55% | 29% | 14 | 22 | 87% |
| Lenalidomide–rituximab (R2) | 147 | 80% | 51% | 39 | 37 | 93% |
| P | <.0001 | .004 | <.0001 | <.0001 | .02 |
| Treatment arm . | Number of patients* . | ORR . | CRR . | PFS, median (mo) . | DOR, median (mo) . | 2-y OS . |
|---|---|---|---|---|---|---|
| Rituximab single agent | 148 | 55% | 29% | 14 | 22 | 87% |
| Lenalidomide–rituximab (R2) | 147 | 80% | 51% | 39 | 37 | 93% |
| P | <.0001 | .004 | <.0001 | <.0001 | .02 |
CRR, complete response rate; DOR, duration of response; ORR, overall response rate; OS, overall survival.
All detailed results are provided for patients with follicular lymphoma.